Gli studenti sono ricevuti il Martedì dalle ore 11:30 alle 13:30 ed il Mercoledì dalle ore 12:00 alle 13:00. E' vivamente consigliato di prendere appuntamento via e-mail o telefonica.
Renato Corradetti obtained the Degrees of M.D. (1977) and of Specialist in Neurology (1982) at Florence University. Researcher (1981-1992), Associate Professor of Pharmacology (1992-2001) he is Professor of Pharmacology at Florence University. His research field is the pharmacological modulation of neurotransmission and synaptic plasticity (long-term potentiation: LTP) in the CNS using electrophysiological and neurochemical in vitro approaches, often in combination. The role of a number of neurotransmitters (adenosine, 5-HT, glutamate, GABA) in hippocampal neurotransmission in adult rats and during development and/or in pathological states (epileptic-like conditions, anoxia) have been investigated. Furthermore, neurophysiological and neurochemical correlates of LTP as well as the effects of several drugs on synaptic plasticity have been studied in detail, including the inhibitory action of 5-HT on LTP induction and the pharmacological identification of 5-HT receptors involved therein. The electrophysiological effects of novel antagonists at 5-HT3 (Itasetron) and 5-HT1A (WAY 100635) receptors on neurotransmission in the hippocampus and raphe have been characterised. Recently, hisresearch has been focussed on the study of the mechanisms of (auto)regulation of serotonergic neuron activity by somatodendritic 5-HT1A receptors (termed autoinhibition). Using a transgenic mouse that overexpress 5-HT1A receptors selectively in serotonergic neurons of the Raphe (Htr1ARO mouse line), described the appearance of a phenotype that could model the Sudden Infant Death Syndrome (SIDS) and part of the ongoing research is directed in understanding the physiological mechanisms that are impaired by 5-HT1A receptor overexpression and are potentially correlated with SIDS. In parallel, other mechanisms implicated in physiological autoinhibition (i.e. 5-HT synthesis, re-uptake, and metabolism) are under investigation using transgenic mice that bear risk factors for human pathology (e.g. TpH2 or SERT impairment for depression). Since 1985, Prof. Corradetti received national and local grants (from MURST, CNR, University of Florence, ECRF) as well as from the European Commission: BIO-CT96-0752 and QLG3-2002-00809,LSHM-CT2004-503474